Clinical • Real-world evidence • BRCA Biomarker • PARP Biomarker
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • FGFR3 (Fibroblast growth factor receptor 3) • PALB2 (Partner and localizer of BRCA2) • CDK12 (Cyclin dependent kinase 12)
|
BRAF V600E • BRCA1 mutation • EGFR mutation • PIK3CA mutation • BRAF V600 • NTRK3 fusion • EGFR exon 19 deletion • RET fusion • ATM mutation • MET exon 14 mutation • PALB2 mutation • FGFR3 mutation • ROS1 fusion • CDK12 mutation • RET M918T • HER-2 S310F • FGFR3 fusion • EGFR mutation + PIK3CA mutation • BRAF amplification
|
Lynparza (olaparib) • Gilotrif (afatinib) • Vitrakvi (larotrectinib) • Nerlynx (neratinib) • Piqray (alpelisib) • Balversa (erdafitinib) • Mektovi (binimetinib)